Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy.

Fujimori S, Takahashi Y, Gudis K, Seo T, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C.

J Gastroenterol. 2011 Jan;46(1):57-64. doi: 10.1007/s00535-010-0332-3. Epub 2010 Oct 6.

PMID:
20924615
2.

Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study.

Niwa Y, Nakamura M, Ohmiya N, Maeda O, Ando T, Itoh A, Hirooka Y, Goto H.

J Gastroenterol. 2008;43(4):270-6. doi: 10.1007/s00535-007-2155-4. Epub 2008 May 6.

PMID:
18458842
3.

A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury.

Kurokawa S, Katsuki S, Fujita T, Saitoh Y, Ohta H, Nishikawa K, Sato Y, Sato Y, Ohira K, Yamada M, Kato M.

J Gastroenterol. 2014 Feb;49(2):239-44. doi: 10.1007/s00535-013-0805-2. Epub 2013 Apr 18. Erratum in: J Gastroenterol. 2014 Feb;49(2):373.

PMID:
23595613
4.

Prevention of nonsteroidal anti-inflammatory drug-induced small-intestinal injury by prostaglandin: a pilot randomized controlled trial evaluated by capsule endoscopy.

Fujimori S, Seo T, Gudis K, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C.

Gastrointest Endosc. 2009 Jun;69(7):1339-46. doi: 10.1016/j.gie.2008.08.017. Epub 2009 Feb 24.

PMID:
19243767
5.

Aspirin-induced small bowel injuries and the preventive effect of rebamipide.

Mizukami K, Murakami K, Abe T, Inoue K, Uchida M, Okimoto T, Kodama M, Fujioka T.

World J Gastroenterol. 2011 Dec 14;17(46):5117-22. doi: 10.3748/wjg.v17.i46.5117.

6.

A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate-to-severe small intestinal damage.

Watanabe T, Takeuchi T, Handa O, Sakata Y, Tanigawa T, Shiba M, Naito Y, Higuchi K, Fujimoto K, Yoshikawa T, Arakawa T.

PLoS One. 2015 Apr 15;10(4):e0122330. doi: 10.1371/journal.pone.0122330. eCollection 2015.

7.

Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study.

Kuramoto T, Umegaki E, Nouda S, Narabayashi K, Kojima Y, Yoda Y, Ishida K, Kawakami K, Abe Y, Takeuchi T, Inoue T, Murano M, Tokioka S, Higuchi K.

BMC Gastroenterol. 2013 May 14;13:85. doi: 10.1186/1471-230X-13-85.

8.

Muscovite is protective against non-steroidal anti-inflammatory drug-induced small bowel injury.

Huang C, Lu B, Fan YH, Zhang L, Jiang N, Zhang S, Meng LN.

World J Gastroenterol. 2014 Aug 21;20(31):11012-8. doi: 10.3748/wjg.v20.i31.11012.

9.

Mucosal protective agents prevent exacerbation of NSAID-induced small intestinal lesions caused by antisecretory drugs in rats.

Satoh H, Amagase K, Takeuchi K.

J Pharmacol Exp Ther. 2014 Feb;348(2):227-35. doi: 10.1124/jpet.113.208991. Epub 2013 Nov 19.

10.

Preventive efficacy and safety of rebamipide in nonsteroidal anti-inflammatory drug-induced mucosal toxicity.

Kim JH, Park SH, Cho CS, Lee ST, Yoo WH, Kim SK, Kang YM, Rew JS, Park YW, Lee SK, Lee YC, Park W, Lee DH.

Gut Liver. 2014 Jul;8(4):371-9. doi: 10.5009/gnl.2014.8.4.371. Epub 2013 Dec 24.

11.

Effects of rebamipide on nephrotoxicity associated with selected NSAIDs in rats.

Wood RC 3rd, Wyatt JE, Bullins KW, Hanley AV, Hanley GA, Denham JW, Panus PC, Harirforoosh S.

Eur J Pharmacol. 2013 Nov 15;720(1-3):138-46. doi: 10.1016/j.ejphar.2013.10.035. Epub 2013 Oct 24.

PMID:
24365796
12.

Geranylgeranylacetone protects against small-intestinal injuries induced by diclofenac in patients with rheumatic diseases: a prospective randomized study.

Xiong L, Huang X, Li L, Yang X, Liang L, Zhan Z, Ye Y, Chen M.

Dig Liver Dis. 2015 Apr;47(4):280-4. doi: 10.1016/j.dld.2015.01.005. Epub 2015 Jan 20.

PMID:
25660821
13.

Preventive effects of rebamipide on NSAID-induced gastric mucosal injury and reduction of gastric mucosal blood flow in healthy volunteers.

Kim HK, Kim JI, Kim JK, Han JY, Park SH, Choi KY, Chung IS.

Dig Dis Sci. 2007 Aug;52(8):1776-82. Epub 2007 Apr 5.

PMID:
17410467
15.

Irsogladine improves small-intestinal injuries in regular users of nonsteroidal anti-inflammatory drugs.

Isomura Y, Yamaji Y, Yamada A, Watanabe Y, Suzuki H, Kobayashi Y, Yoshida S, Watabe H, Hirata Y, Yoshida H, Koike K.

Gastrointest Endosc. 2014 Jul;80(1):118-25. doi: 10.1016/j.gie.2013.12.030. Epub 2014 Feb 8.

PMID:
24518124
16.

Rebamipide does not protect against naproxen-induced gastric damage: a randomized double-blind controlled trial.

Gagliano-Jucá T, Moreno RA, Zaminelli T, Napolitano M, Magalhães AF, Carvalhaes A, Trevisan MS, Wallace JL, De Nucci G.

BMC Gastroenterol. 2016 Jun 4;16(1):58. doi: 10.1186/s12876-016-0472-x.

17.

Rebamipide protects against indomethacin-induced gastric mucosal injury in healthy volunteers in a double-blind, placebo-controlled study.

Naito Y, Yoshikawa T, Iinuma S, Yagi N, Matsuyama K, Boku Y, Fujii T, Yoshida N, Kondo M, Sasaki E.

Dig Dis Sci. 1998 Sep;43(9 Suppl):83S-89S.

PMID:
9753232
18.

Distribution of small intestinal mucosal injuries as a result of NSAID administration.

Fujimori S, Gudis K, Takahashi Y, Seo T, Yamada Y, Ehara A, Kobayashi T, Mitsui K, Yonezawa M, Tanaka S, Tatsuguchi A, Sakamoto C.

Eur J Clin Invest. 2010 Jun;40(6):504-10. doi: 10.1111/j.1365-2362.2010.02290.x. Epub 2010 Apr 14.

PMID:
20412292
19.

Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans.

Scarpignato C, Dolak W, Lanas A, Matzneller P, Renzulli C, Grimaldi M, Zeitlinger M, Bjarnason I.

Gastroenterology. 2017 Apr;152(5):980-982.e3. doi: 10.1053/j.gastro.2016.12.007. Epub 2016 Dec 19.

20.

Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.

Hawkey CJ, Ell C, Simon B, Albert J, Keuchel M, McAlindon M, Fortun P, Schumann S, Bolten W, Shonde A, Hugot JL, Yu V, Arulmani U, Krammer G, Rebuli R, Toth E.

Clin Gastroenterol Hepatol. 2008 May;6(5):536-44. doi: 10.1016/j.cgh.2007.12.023. Epub 2008 Jan 31.

PMID:
18242145

Supplemental Content

Support Center